Session VII: Gastric Cancer: Presentation of selected abstracts
Overall survival results from a Phase III trial of trifluridine/tipiracil vs. placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS)
Josep Tabernero, et al., LBA-002
The authors of the study conclude that
" trifluridine/tipiracil (FTD/TPI) showed a meaningful and statistically significant improvement in OS and PFS compared with placebo in heavily pretreated mGC."
-31% reduction in risk of death (HR, 0.69,95%CI 0.56-085; p=0.0003)
- 2.1 months improvement in median OS (5.7 vs. 3.6 months)
FTD/TPI showed a predictable and manageable safety profile, consistent with that seen previously in patients with mCRC
FTD/TPI represents an effective treatment option with a manageable safety profile for patients with heavily pretreated mGC"
See also the subgroup Analysis
See the webcast from this presentation
See statement Josep Tabernero below
See statement Alexander Siebenhüner below
Press Release SERVIER & TAIHO
KEYNOTE-061: phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer
Kohei Shitara, et al., LBA-005
The authors of the study conclude that "Pembrolizumab did not significantly improve OS vs paclitaxel in patients with previously treated G/GEJ cancer and PD-L1 CPS ≥1, although a benefit for pembrolizumab emerged with long-term follow-up. Pembrolizumab had a better safety profile than paclitaxel. The pembrolizumab treatment effect was more evident in patients with ECOG PS 0, those with greater PD-L1 expression, and those with MSI-H tumors. Trials of pembrolizumab as monotherapy and as part of combination therapy for G/GEJ cancer are ongoing."